OGN
Organon & CoNYSEHEALTHCAREDRUG MANUFACTURERS - GENERAL
Key Statistics
Market Cap
$1.53B
P/E Ratio
8.14
EPS
$0.72
Beta
0.64
52W High
$13.12
52W Low
$5.69
50-Day MA
$7.18
200-Day MA
$8.45
Dividend Yield
5.56%
Profit Margin
3.01%
Forward P/E
5.09
PEG Ratio
—
About Organon & Co
Organon & Co. is an American pharmaceutical company headquartered in Jersey City, New Jersey. Organon specializes in the following core therapeutic fields: reproductive medicine, contraception, psychiatry, Hormone replacement therapy (HRT), and anesthesia. The company sells to international markets.
Fundamentals
| Revenue (TTM) | $6.22B |
| Gross Profit (TTM) | $3.38B |
| EBITDA | $1.65B |
| Operating Margin | 16.20% |
| Return on Equity | 30.60% |
| Return on Assets | 6.22% |
| Revenue/Share (TTM) | $23.95 |
| Book Value | $2.89 |
| Price-to-Book | 2.20 |
| Price-to-Sales (TTM) | 0.24 |
| EV/Revenue | 1.565 |
| EV/EBITDA | 7.54 |
| Quarterly Earnings Growth (YoY) | -55.80% |
| Quarterly Revenue Growth (YoY) | -5.30% |
| Shares Outstanding | $260.32M |
| Float | $258.71M |
| % Insiders | 0.33% |
| % Institutions | 77.44% |
Analyst Ratings
Consensus ($9.00 target)
1
Strong Buy3
Hold4
Strong SellData last updated: 4/9/2026